These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 19384597

  • 21. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease.
    Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN.
    Neuroscience; 2008 Oct 28; 156(4):830-40. PubMed ID: 18817851
    [Abstract] [Full Text] [Related]

  • 22. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
    Konieczny J, Czarnecka A, Kamińska K, Lenda T, Nowak P.
    Behav Brain Res; 2015 Apr 15; 283():203-14. PubMed ID: 25655509
    [Abstract] [Full Text] [Related]

  • 23. Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
    Campbell JC, Jeyamohan SB, De La Cruz P, Chen N, Shin D, Pilitsis JG.
    Behav Brain Res; 2014 Dec 15; 275():114-9. PubMed ID: 25205367
    [Abstract] [Full Text] [Related]

  • 24. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
    Han B, Jin HJ, Song MY, Wang T, Zhao H.
    Parkinsonism Relat Disord; 2014 Nov 15; 20(11):1191-5. PubMed ID: 25219971
    [Abstract] [Full Text] [Related]

  • 25. L-linalool exerts a neuroprotective action on hemiparkinsonian rats.
    de Lucena JD, Gadelha-Filho CVJ, da Costa RO, de Araújo DP, Lima FAV, Neves KRT, de Barros Viana GS.
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Jun 15; 393(6):1077-1088. PubMed ID: 31938809
    [Abstract] [Full Text] [Related]

  • 26. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA.
    J Pharmacol Exp Ther; 1987 Jan 15; 240(1):167-76. PubMed ID: 3100767
    [Abstract] [Full Text] [Related]

  • 27. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
    Doucet JP, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin BJ, Chen JS, Iadarola MJ, St-Jean M, Wigle N, Blanchet P, Grondin R, Robertson GS.
    Eur J Neurosci; 1996 Feb 15; 8(2):365-81. PubMed ID: 8714707
    [Abstract] [Full Text] [Related]

  • 28. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
    Breese GR, Napier TC, Mueller RA.
    J Pharmacol Exp Ther; 1985 Aug 15; 234(2):447-55. PubMed ID: 3926987
    [Abstract] [Full Text] [Related]

  • 29. Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease.
    Andrzejewski K, Budzińska K, Zaremba M, Kaczyńska K.
    Neuroscience; 2016 Mar 01; 316():192-200. PubMed ID: 26705738
    [Abstract] [Full Text] [Related]

  • 30. Respiratory pattern and phrenic and hypoglossal nerve activity during normoxia and hypoxia in 6-OHDA-induced bilateral model of Parkinson's disease.
    Andrzejewski K, Jampolska M, Zaremba M, Joniec-Maciejak I, Boguszewski PM, Kaczyńska K.
    J Physiol Sci; 2020 Mar 11; 70(1):16. PubMed ID: 32160868
    [Abstract] [Full Text] [Related]

  • 31. Thioperamide, an H₃ receptor antagonist prevents [³H]glucose uptake in brain of adult rats lesioned as neonates with 5,7-dihydroxytryptamine.
    Jośko J, Drab J, Nowak P, Szkilnik R, Körossy E, Boroń D, Brus H, Kostrzewa RM, Brus R.
    Neurotox Res; 2011 Jul 11; 20(1):93-6. PubMed ID: 20838953
    [Abstract] [Full Text] [Related]

  • 32. Intranigral injection of the H3 agonist immepip and systemic apomorphine elicit ipsilateral turning behaviour in naive rats, but reduce contralateral turning in hemiparkinsonian rats.
    García-Ramírez M, Aceves J, Arias-Montaño JA.
    Behav Brain Res; 2004 Oct 05; 154(2):409-15. PubMed ID: 15313028
    [Abstract] [Full Text] [Related]

  • 33. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis.
    Metz GA, Tse A, Ballermann M, Smith LK, Fouad K.
    Eur J Neurosci; 2005 Aug 05; 22(3):735-44. PubMed ID: 16101755
    [Abstract] [Full Text] [Related]

  • 34. Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats.
    Anichtchik OV, Huotari M, Peitsaro N, Haycock JW, Männistö PT, Panula P.
    Eur J Neurosci; 2000 Nov 05; 12(11):3823-32. PubMed ID: 11069577
    [Abstract] [Full Text] [Related]

  • 35. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB, Stephenson G, Ben Shachar D.
    Ann N Y Acad Sci; 2004 Mar 05; 1012():306-25. PubMed ID: 15105275
    [Abstract] [Full Text] [Related]

  • 36. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT, White FJ.
    Synapse; 1992 Mar 05; 10(3):206-16. PubMed ID: 1532677
    [Abstract] [Full Text] [Related]

  • 37. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM, Faull RL, Connor B.
    Neuroscience; 2008 Feb 19; 151(4):1142-53. PubMed ID: 18201835
    [Abstract] [Full Text] [Related]

  • 38. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease.
    Rodríguez Díaz M, Abdala P, Barroso-Chinea P, Obeso J, González-Hernández T.
    Behav Brain Res; 2001 Jul 19; 122(1):79-92. PubMed ID: 11287079
    [Abstract] [Full Text] [Related]

  • 39. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Yuan H, Sarre S, Ebinger G, Michotte Y.
    Brain Res; 2004 Nov 05; 1026(1):95-107. PubMed ID: 15476701
    [Abstract] [Full Text] [Related]

  • 40. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity.
    Sharma S, Taliyan R, Singh S.
    Behav Brain Res; 2015 Sep 15; 291():306-314. PubMed ID: 26048426
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.